Literature DB >> 6607288

Heterogeneity of infection enhancement of dengue 2 strains by monoclonal antibodies.

S B Halstead, C N Venkateshan, M K Gentry, L K Larsen.   

Abstract

Seven dengue (DEN) 2 virus strains were studied for antibody-dependent enhancement (ADE) of infection in P388D1 mouse macrophage-like cells by using a panel of five DEN 2 monoclonal antibodies. DEN 2 strains were of diverse temporal, geographic, and disease origins. By hemagglutination inhibition and a plaque-reduction neutralization test in LLC-MK2 cells, two of the monoclonal antibodies were type specific and three were flavivirus group reactive. In LLC-MK2 cells, the seven DEN 2 viruses each were neutralized by all five monoclonal antibodies. In P388D1 cells, two DEN 2 strains were enhanced by only three monoclonal antibodies, two by four antibodies, and three by all five antibodies, demonstrating that in some instances enhancement is epitope related and not a concentration-dependent function of virus-antibody interactions. However, ADE did not segregate with determinants exhibiting either the flavivirus group or the dengue type specificity. The presence or absence of enhancement determinants on DEN 2 strains did not correlate with the geographic origin of virus or the severity of disease yielding the strain. The heterogeneous distribution of enhancement determinants may provide a valence mechanism contributing to a multiple increase of infection enhancement in macrophages.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6607288

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  44 in total

1.  Infection of human cells by dengue virus is modulated by different cell types and viral strains.

Authors:  M S Diamond; D Edgil; T G Roberts; B Lu; E Harris
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

2.  Public versus personal serotypes of a viral quasispecies.

Authors:  Lukas Hunziker; Adrian Ciurea; Mike Recher; Hans Hengartner; Rolf M Zinkernagel
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-02       Impact factor: 11.205

3.  Variable surface epitopes in the crystal structure of dengue virus type 3 envelope glycoprotein.

Authors:  Yorgo Modis; Steven Ogata; David Clements; Stephen C Harrison
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

4.  Expression of the structural proteins of dengue 2 virus and yellow fever virus by recombinant vaccinia viruses.

Authors:  Y S Hahn; E M Lenches; R Galler; C M Rice; J Dalrymple; J H Strauss
Journal:  Arch Virol       Date:  1990       Impact factor: 2.574

Review 5.  Barriers to preclinical investigations of anti-dengue immunity and dengue pathogenesis.

Authors:  Ashley L St John; Soman N Abraham; Duane J Gubler
Journal:  Nat Rev Microbiol       Date:  2013-05-08       Impact factor: 60.633

6.  Antibody recognition of the dengue virus proteome and implications for development of vaccines.

Authors:  Stefan Fernandez; Emily D Cisney; Alexander P Tikhonov; Barry Schweitzer; Robert J Putnak; Monika Simmons; Robert G Ulrich
Journal:  Clin Vaccine Immunol       Date:  2011-01-26

7.  Small molecule pan-dengue and West Nile virus NS3 protease inhibitors.

Authors:  Lynne Cregar-Hernandez; Guan-Sheng Jiao; Alan T Johnson; Axel T Lehrer; Teri Ann S Wong; Stephen A Margosiak
Journal:  Antivir Chem Chemother       Date:  2011-05-12

8.  Monoclonal antibody analysis of neutralization and antibody-dependent enhancement of feline infectious peritonitis virus.

Authors:  W V Corapi; C W Olsen; F W Scott
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

9.  Generation and characterization of monoclonal antibodies against dengue virus type 1 for epitope mapping and serological detection by epitope-based peptide antigens.

Authors:  Yun-Ching Chen; Hsien-Neng Huang; Chin-Tarng Lin; Yi-Fang Chen; Chwan-Chuen King; Han-Chung Wu
Journal:  Clin Vaccine Immunol       Date:  2007-02-07

10.  Monoclonal antibodies that bind to common epitopes on the dengue virus type 2 nonstructural-1 and envelope glycoproteins display weak neutralizing activity and differentiated responses to virulent strains: implications for pathogenesis and vaccines.

Authors:  Andrew K I Falconar
Journal:  Clin Vaccine Immunol       Date:  2007-12-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.